Live
Funding 2 min read

Sweden’s Omnio raises €2.9 million to advance its plasminogen-based therapy for hard-to-heal chronic wounds

Omnio, a Umeå-based biotech startup, has raised €2.9 million to further develop its plasminogen-based therapy targeting chronic wounds. This funding follows a previous round, enabling the company to progress towards clinical studies.

Nordic Startup News desk Based on reporting by EU-Startups Sweden · Single-source report
Read original reporting ↗
Image: EU-Startups Sweden

Omnio raised €2.9 million to advance its plasminogen-based therapy for chronic wounds. This funding supports the company's goal of moving towards clinical studies following a €4.3 million round completed earlier.

The latest investment, from existing shareholders, underscores the confidence in Omnio's ongoing development shaped by research from Umeå University. The funds will facilitate further progress towards clinical trials for its groundbreaking therapy.

This funding positions Omnio to continue its innovative research, potentially placing it at the forefront of solutions for chronic wound management.

Reporting sources

Where this story comes from

1 reference

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

E EU-Startups Swedeneu-startups.com
EU-Startups Sweden Open source

Sweden’s Omnio raises €2.9 million to advance its plasminogen-based therapy for hard-to-heal chronic wounds

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

Story history

No reviewed connections found in the current history window.

About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority7 / 10

Priority

Source coverageSingle-source report

Single-source report

ConfidenceLimited

44 / 100 · one source

Source basis

Grounded in the publisher material listed below.

Confirmation

No second independent source has been matched to this story yet.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 1 independent source
  • 1 concrete event indicator
  • editorial priority

Source monitoring: 100% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.